Endocrine Abstracts

Background: In January 2018, the 8th edition of the AJCC/TNM staging system for differentiated thyroid cancer (DTC) was introduced in clinical practice. Studies evaluating this 8th edition so far only comprised patients with papillary thyroid cancer (PTC) or made no distinction between PTC and follicular thyroid cancer (FTC). Therefore, we evaluated the prognostic value of the AJCC/TNM 8th edition in a European population with DTC, and subsequently distinguished PTC and FTC pa...

BackgroundThe 2015 American Thyroid Association (ATA) Risk Stratification System for differentiated thyroid cancer (DTC) is designed to predict response to therapy and recurring disease. Although age is not incorporated as a risk factor, recent research suggests that the addition of age can improve this system. However, these studies comprised low number of patients with ATA High Risk, low numbers of patients with follicular thyroid cancer (FTC), and did...

Background: Adrenocortical carcinoma (ACC) is a rare but devastating malignancy (5-year survival 18–57%), with limited treatment options. Currently, mitotane is the first-line medical treatment for metastatic ACC and is used in the adjuvant setting after surgery to prevent recurrence. Mitotane is an adrenolytic drug that is thought to act by disruption of mitochondria with subsequent activation of apoptosis. However, mitotane treatment comes with many drawbacks, such as s...

Introduction: Pheochromocytoma, a rare catecholamine-secreting adrenal tumor, can cause hypertension and life-threatening complications. Hereditary cases have an increased risk of developing bilateral disease. Standard treatment involves radical adrenalectomy, leading to adrenal insufficiency in bilateral cases. Partial adrenalectomy aims to preserve adrenal function but has higher recurrence rates. This study compares outcomes of partial vs radical adrenalectomy in hereditary...